152 related articles for article (PubMed ID: 33098911)
1. Anticancer drug-loaded mesenchymal stem cells for targeted cancer therapy.
Takayama Y; Kusamori K; Tsukimori C; Shimizu Y; Hayashi M; Kiyama I; Katsumi H; Sakane T; Yamamoto A; Nishikawa M
J Control Release; 2021 Jan; 329():1090-1101. PubMed ID: 33098911
[TBL] [Abstract][Full Text] [Related]
2. Maximized nanodrug-loaded mesenchymal stem cells by a dual drug-loaded mode for the systemic treatment of metastatic lung cancer.
Yao S; Li X; Liu J; Sun Y; Wang Z; Jiang Y
Drug Deliv; 2017 Nov; 24(1):1372-1383. PubMed ID: 28920712
[TBL] [Abstract][Full Text] [Related]
3. Migration of mesenchymal stem cells to tumor xenograft models and
Kalimuthu S; Zhu L; Oh JM; Gangadaran P; Lee HW; Baek SH; Rajendran RL; Gopal A; Jeong SY; Lee SW; Lee J; Ahn BC
Int J Med Sci; 2018; 15(10):1051-1061. PubMed ID: 30013447
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin Loaded Silica Nanoparticles with Dual Modification as a Tumor-Targeted Drug Delivery System for Colon Cancer Therapy.
Lin YQ; Zhang J; Liu SJ; Ye H
J Nanosci Nanotechnol; 2018 Apr; 18(4):2330-2336. PubMed ID: 29442900
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy.
Zhao Y; Tang S; Guo J; Alahdal M; Cao S; Yang Z; Zhang F; Shen Y; Sun M; Mo R; Zong L; Jin L
Sci Rep; 2017 Mar; 7():44758. PubMed ID: 28303966
[TBL] [Abstract][Full Text] [Related]
6. Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy.
Zhang X; Yao S; Liu C; Jiang Y
Biomaterials; 2015 Jan; 39():269-81. PubMed ID: 25468377
[TBL] [Abstract][Full Text] [Related]
7. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
8. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
9. Cell-based interferon gene therapy using proliferation-controllable, interferon-releasing mesenchymal stem cells.
Tsujimura M; Kusamori K; Katsumi H; Sakane T; Yamamoto A; Nishikawa M
Sci Rep; 2019 Dec; 9(1):18869. PubMed ID: 31827180
[TBL] [Abstract][Full Text] [Related]
10. Long-term drug modification to the surface of mesenchymal stem cells by the avidin-biotin complex method.
Takayama Y; Kusamori K; Hayashi M; Tanabe N; Matsuura S; Tsujimura M; Katsumi H; Sakane T; Nishikawa M; Yamamoto A
Sci Rep; 2017 Dec; 7(1):16953. PubMed ID: 29208980
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
12. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging.
Wang H; Cao F; De A; Cao Y; Contag C; Gambhir SS; Wu JC; Chen X
Stem Cells; 2009 Jul; 27(7):1548-58. PubMed ID: 19544460
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
Deng C; Zhang Q; Fu Y; Sun X; Gong T; Zhang Z
ACS Appl Mater Interfaces; 2017 Jan; 9(2):1280-1292. PubMed ID: 28009503
[TBL] [Abstract][Full Text] [Related]
14. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
15. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
16. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
17. Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy.
Cao S; Guo J; He Y; Alahdal M; Tang S; Zhao Y; Yang Z; Gao H; Hu W; Jiang H; Qin L; Jin L
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):642-652. PubMed ID: 29457930
[TBL] [Abstract][Full Text] [Related]
18. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy.
Li L; Guan Y; Liu H; Hao N; Liu T; Meng X; Fu C; Li Y; Qu Q; Zhang Y; Ji S; Chen L; Chen D; Tang F
ACS Nano; 2011 Sep; 5(9):7462-70. PubMed ID: 21854047
[TBL] [Abstract][Full Text] [Related]
19. A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis.
Chen Y; Peng J; Han M; Omar M; Hu D; Ke X; Lu N
J Drug Target; 2015 May; 23(4):335-46. PubMed ID: 25541466
[TBL] [Abstract][Full Text] [Related]
20. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
